The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
Authors list
Peter Connick Madhan Kolappan Rickie Patani Michael A Scott Charles Crawley Xiao-Ling He Karen Richardson Kelly Barber Daniel J Webber Claudia AM Wheeler-Kingshott Daniel J Tozer Rebecca S Samson David L Thomas Ming-Qing Du Shi L Luan Andrew W Michell Daniel R Altmann Alan J Thompson David H Miller Alastair Compston Siddharthan ChandranAbstract
No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes--the "sentinel lesion approach".
Full text links
Publisher website (DOI) 10.1186/1745-6215-12-62
Europe PubMed Central 21366911
Pubmed 21366911
Keywords
Type of publication